CHMP recommends Merck's Bavencio for Merkel cell carcinoma

EMA's CHMP recommended approval of Bavencio avelumab (MSB0010718C, PF-06834635) from Merck KGaA (Xetra:MRK) to treat metastatic Merkel cell carcinoma (MCC). A decision is expected this quarter. Merck...